Share on StockTwits

Equities researchers at Stifel Nicolaus started coverage on shares of Argos Therapeutics (NASDAQ:ARGS) in a research report issued on Tuesday. The firm set a “buy” rating and a $16.00 price target on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 132.90% from the company’s current price.

Argos Therapeutics (NASDAQ:ARGS) opened at 6.87 on Tuesday. Argos Therapeutics has a 1-year low of $5.611 and a 1-year high of $13.74. The stock’s 50-day moving average is $6.69 and its 200-day moving average is $8.32. The company’s market cap is $135.0 million.

Argos Therapeutics (NASDAQ:ARGS) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.61) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.60) by $0.01. The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.27 million. On average, analysts predict that Argos Therapeutics will post $-2.56 EPS for the current fiscal year.

Argos Therapeutics Inc is a United States-based biopharmaceutical company. The company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis technology platform.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.